The past few years have seen the leveling off of new molecular entities (NMEs) reaching the market,1-3 partly as a result of increasing drug development costs and higher regulatory standards for drug approval. Yet many opportunities still exist in this changing pharmaceutical market for both innovator and generic pharmaceutical companies who are willing to seek new ways to innovate. One key approach is by finding novel ways of working with current drug assets.
Enhancing drug product portfolios for nasal aerosols and buccal spray delivery systems
A changing market environment and ways nasal aerosols and buccal sprays can provide opportunities